Valeant Pharmaceuticals International (VRX) is under pressure this morning after a New York Times article entitled "Valeant's Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers."
Valeant Pharmaceuticals International gapped open lower this morning and has continued to decline in early trade. Shares are now down 10.17 at $172.15. The stock is trading near the middle of a 1-week range.
For comments and feedback: editorial@rttnews.com